Genta Clinical Programs Featured at American Society of Hematology Meeting

• Addition of oblimersen (Bcl-2 antisense) to fludarabine/cyclophosphamide for relapsed/refractory chronic lymphocytic leukemia extends survival in patients who achieve CR/nPR: Results from a randomized Phase 3 study.
  Oral session:  Tuesday, December 11, 2007; 7:30 am
  Note:  This abstract has been selected for a featured press briefing sponsored by ASH on Sunday December 9 at 9:30 am.
• Oblimersen (Genasense®), a phosphorothioate Bcl-2 antisense oligonucleotide (ASO), can be safely administered by bolus subcutaneous (SC) injection and brief IV Infusion.  Publication.
• Phase 1 assessment of G4544, an orally bioavailable formulation of gallium nitrate.  Publication.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future.  Forward-looking statements include, without limitation, statements about:

• the Company's ability to obtain necessary regulatory approval for Genasense® from the U.S. Food and Drug Administration ("FDA") or European Medicines Agency ("EMEA");
• the safety and efficacy of the Company's products or product candidates;
• the Company's assessment of its clinical trials;
• the commencement and completion of clinical trials;
• the Company's ability to develop, manufacture, license and sell its products or product candidates;
• the Company's ability to enter into and successfully execute license and collaborative agreements, if any;
• the adequacy of the Company's capital resources and cash flow projections, and the Company's ability to obtain sufficient financing to maintain the Company's planned operations;
• the adequacy of the Company's patents and proprietary rights;
• the impact of litigation that has been brought against the Company and its officers and directors and any proposed settlement of such litigation;
• the Company's ability to retain compliance with the NASDAQ's listing qualifications; and
• the other risks described under Certain Risks and Uncertainties Related to the Company's Business, as contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements.   There are a number of factors that could cause actual results and developments to differ materially.  For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2006 and its most recent quarterly report on Form 10-Q.

CONTACT:

Nichol Harber
Genta Investor Relations
info@genta.com
908-286-3980